Suggested remit: To evaluate the benefits and costs of arimoclomol within its marketing authorisation for treating Niemann-Pick disease type C for national commissioning by NHS England.
Status Proposed
Process HST
ID number 1312

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
17 May 2021 Please note that following on from advice received from the company this evaluation has been rescheduled. Therefore, we now anticipate that the evaluation will begin during early November 2021 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid-Jan 2022.
09 October 2020 (14:00) Scoping workshop
19 August 2020 - 17 September 2020 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE highly specialised technologies guidance